Skip Navigation



Rheumatology Advance Access published online on April 26, 2005

Rheumatology, doi:10.1093/rheumatology/keh658
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/8/1008    most recent
keh658v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmeling, H.
Right arrow Articles by Horneff, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmeling, H.
Right arrow Articles by Horneff, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received September 9, 2004
Accepted March 18, 2005

Concise Report

Etanercept and uveitis in patients with juvenile idiopathic arthritis

H. Schmeling 1* and G. Horneff 1

1 Department of Paediatrics, Martin Luther University, Halle-Wittenberg, Halle, Germany

* To whom correspondence should be addressed.
H. Schmeling, E-mail: heinrike.schmeling{at}medizin.uni-halle.de


   Abstract

Objectives. Etanercept has been shown to be effective for the treatment of juvenile idiopathic arthritis (JIA). The therapeutic efficacy of etanercept for chronic uveitis, a major complication of JIA, has not been evaluated so far. Therefore, the appearance of chronic anterior uveitis and associated complications in JIA patients treated with etanercept was evaluated.

Methods. Questionnaires were sent to paediatric rheumatologists treating a total of 310 JIA patients with etanercept.

Results. Two hundred and twenty-nine questionnaires (74%) were returned. Before institution of etanercept, 31 patients (13.5%) had a history of uveitis with a total of 102 flares. Twenty-eight patients belonged to the high-risk groups of the oligoarticular and seronegative polyarticular subtypes. Upon commencing etanercept, 32 courses of uveitis occurred in 19 patients and in two further patients (1%) in whom uveitis occurred for the first time. Twenty of them belonged to the high-risk group. Uveitis during etanercept therapy occurred in 12 of 15 patients (80%) with more than one course of uveitis, and in seven of 16 patients (44%) with only one course before etanercept therapy. Complications were noted in 12 patients before and in eight during etanercept treatment. In 87% of the uveitis patients, arthritis demonstrated a significant or complete response.

Conclusion. During treatment with etanercept, there were both relapses and first courses of uveitis. In addition, the frequency and severity of uveitis seemed not to be influenced by etanercept. In particular, patients with relapsing uveitis before institution of etanercept treatment remain at high risk of the development of uveitis flares despite etanercept treatment.

Keywords: Uveitis; Etanercept; Juvenile idiopathic arthritis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
T. Cobo-Ibanez, M. del Carmen Ordonez, S. Munoz-Fernandez, R. Madero-Prado, and E. Martin-Mola
Do TNF-blockers reduce or induce uveitis?
Rheumatology, May 1, 2008; 47(5): 731 - 732.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
P. Tynjala, K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen, and P. Lahdenne
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis
Rheumatology, March 1, 2008; 47(3): 339 - 344.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.